Comparison · NCT04412057-deaths
CERC-002 vs Placebo: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CERC-002 vs Placebo: deaths from any cause. Trial comparisons, record NCT04412057-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04412057-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.1 | 0.0396 | 0.231 | wilson | |
| Risk in group 2 | 0.214 | 0.117 | 0.359 | wilson | |
| Risk difference, group 1 minus group 2 | -0.114 | -0.271 | 0.0485 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.467 | 0.156 | 1.4 | log | |
| Odds ratio, group 1 over group 2 | 0.407 | 0.115 | 1.45 | log | |
| Number needed to treat, for one fewer death from any cause on CERC-002 than on Placebo | 8.75 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CERC-002 | CERC-002: Administered once subcutaneously at 16 mg/kg dose up to a maximum dose of 1200 mg. | 4 | 40 | EG000 |
| Group 2 | Placebo | Placebo: Administered once subcutaneously | 9 | 42 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
All adverse events were collected from the time of the informed consent until the end of study (Day 60). Therefore all serious and non-serious events are included regardless of meeting or not meeting the study definition of treatment emergent (eg, pre-treatment events are included).
Source ClinicalTrials.gov
Trial
- Title
- Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
- NCT number
- NCT04412057
- Phases
- PHASE2
- Conditions
- COVID-19 Pneumonia, Acute Lung Injury, ARDS
- Interventions
- CERC-002, Placebo
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Results first posted
- 2022-03-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04412057?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04412057-deaths